Related Experiment Videos
Soluble Flt-1 gene therapy for peritoneal metastases using HVJ-cationic liposomes
1Department of Surgery and Surgical Basic Science, Graduate School of Medicine, Kyoto University, Japan.
Gene Therapy
|June 29, 2000
Summary
Gene therapy using soluble Flt-1 delivered via HVJ-liposomes effectively suppressed peritoneal cancer metastasis in mice. This approach reduced tumor spread and microvessel formation, significantly improving survival rates in preclinical models.
Area of Science:
- Oncology
- Gene Therapy
- Molecular Biology
Background:
- Vascular Endothelial Growth Factor (VEGF) is crucial for tumor angiogenesis.
- Targeting VEGF signaling is a key strategy in cancer therapy.
- Peritoneal metastasis presents a significant clinical challenge.
Purpose of the Study:
- To evaluate the efficacy of gene therapy using soluble Flt-1 against cancer peritoneal metastasis.
- To assess the potential of HVJ-Fex, a liposomal delivery system for soluble Flt-1, in preclinical cancer models.
Main Methods:
- Utilized peritoneal metastasis models with MKN45 gastric cancer and HT1080S fibrosarcoma cells in mice.
- Administered repetitive intraperitoneal injections of HVJ-Fex, encapsulating a plasmid expressing soluble Flt-1.
- Evaluated tumor burden, microvessel density, ascites formation, and survival rates.
Main Results:
- HVJ-Fex treatment significantly reduced disseminated foci and microvessel formation in MKN45 models.
- Mice treated with HVJ-Fex showed significantly longer survival periods.
- In HT1080S models, HVJ-Fex treatment inhibited disseminated foci growth and prevented ascites formation.
Conclusions:
- Peritoneal metastases of certain cancers are highly dependent on VEGF.
- Intraperitoneal gene transfer of soluble Flt-1 using HVJ-cationic liposomes effectively suppresses peritoneal metastasis.
- This gene therapy approach offers a promising strategy for improving survival in peritoneal carcinomatosis.